EMA committee chair honoured for work on orphan drugs

Bruno Sepodes has been given the EURORDIS European Rare Diseases Leadership Award in recognition of work done to involve patients in all decision-making processes.

European Medicines Agency

The chair of the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products has been recognised for involving patients at all stages of the decision-making process around orphan drugs.

Bruno Sepodes has been awarded the EURORDIS (European Organisation for Rare Diseases) European Rare Diseases Leadership Award, which acknowledges the outstanding achievements and exceptional work of individuals who make a difference for patients with rare conditions.

Sepodes, professor of pharmacology and pharmacotherapy at the faculty of pharmacy of the University of Lisbon in Portugal, is also a member of the EMA’s Committee for Medicinal Products for Human Use and Committee for Advanced Therapies.

EURORDIS–Rare Diseases Europe is an alliance of more than 700 patient organisations from more than 60 countries, and is devoted to improving the lives of the 30 million people living with a rare disease in Europe.

Sepodes will receive his award at a ceremony on 28 February 2018.

Last updated
Citation
The Pharmaceutical Journal, January 2018;Online:DOI:10.1211/PJ.2018.20204257